Clincosm LogoSign in Get a demo

TEP-FLT-LMA: Study of the Predictive Marker FLT in Patients Suffering From AML

Sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke (Other)
Overall Status
Withdrawn
CT.gov ID
NCT01599429
Collaborator
(none)
0
Enrollment
1
Location
74
Duration (Months)
0
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Positron emission tomography uses various radioactive tracers to measure the metabolic activity in a none-invasive way, and specially to follow the activity of the disease during the treatments.

Among those new tracers, fluorothymidine (18F-FLT) arouses a lot of interest. This new tool would allow to image and follow time wise acute myeloid leukemia (AML). The investigators want, with the (18F-FLT), to characterise the aggressivity of the tumors and the prognostic before and after chemotherapy treatment.

The aim of this study is to be able to identify earlier the responders, because if they are detected sooner, these patients will benefit from more aggressive treatments.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    0 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Use of FLT-TEP Scan as Predictive Marker and Early Prognostic in Patients Suffering From AML Treated by Chemotherapy
    Study Start Date :
    Oct 31, 2011
    Actual Primary Completion Date :
    Oct 31, 2017
    Actual Study Completion Date :
    Dec 31, 2017

    Outcome Measures

    Primary Outcome Measures

    1. To mesure the pronostic value of metabolic activity in the bone marrow with FLT-PET prior to chemotherapy in patients with AML disease. [September 2015]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Patients 18 years or above at the time of inclusion;

    2. Patients newly diagnosed with acute myeloid leukemia;

    3. No contraindication or intolerance to any of the components of the standard chemotherapy by induction (7+3);

    4. Patients able to give written informed consent.

    Exclusion Criteria:

    1. Patients unable to tolerate decubitus position for at least 45 minutes;

    2. Any previous neoplasia or other neoplasia simultaneously;

    3. Previously treated buy radiotherapy, with bone marrow in the field of radiation;

    4. Other chemotherapy treatment than the standard chemotherapy by induction (7+3), before the second FLT-TEP was done.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Centre Hospitalier Universitaire de Sherbrooke Sherbrooke Quebec Canada J1H 5N4

    Sponsors and Collaborators

    • Centre de recherche du Centre hospitalier universitaire de Sherbrooke

    Investigators

    • Principal Investigator: Éric E Turcotte, MD, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Centre d'imagerie moléculaire de Sherbrooke (CIMS), Centre de recherche Étienne Le-Bel
    • Principal Investigator: Rami Kotb, MD, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Dr Éric E Turcotte, MD, Principal Investigator, Centre de recherche du Centre hospitalier universitaire de Sherbrooke
    ClinicalTrials.gov Identifier:
    NCT01599429
    Other Study ID Numbers:
    • CIMS-2011-01
    First Posted:
    May 16, 2012
    Last Update Posted:
    Apr 14, 2021
    Last Verified:
    Apr 1, 2021
    Keywords provided by Dr Éric E Turcotte, MD, Principal Investigator, Centre de recherche du Centre hospitalier universitaire de Sherbrooke
    AML / LMA

    Study Results

    No Results Posted as of Apr 14, 2021